ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Phase of Trial: Phase II/III
Latest Information Update: 11 Mar 2017
At a glance
- Drugs Nivolumab (Primary) ; Capecitabine; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 28 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2020.
- 24 Feb 2017 Planned number of patients changed from 268 to 680.
- 24 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2020.